EYP-1901 vs Aflibercept for Age-Related Macular Degeneration
(wAMD Trial)
Trial Summary
What is the purpose of this trial?
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are already receiving anti-VEGF injections for your condition, you may need to continue them as part of the study.
What data supports the effectiveness of the drug Aflibercept for treating age-related macular degeneration?
Is EYP-1901 or Aflibercept safe for humans?
How is the drug EYP-1901 (Aflibercept) unique for treating age-related macular degeneration?
Eligibility Criteria
This trial is for individuals with wet Age-Related Macular Degeneration (wAMD), either new or previously treated. Participants must have a certain level of vision, measured by the ETDRS letter score, and if previously treated, they should have had at least two anti-VEGF injections in the past six months.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either EYP-1901 or Aflibercept for the treatment of wet AMD
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Participants may continue to receive treatment for up to 2 years
Treatment Details
Interventions
- Aflibercept
- EYP-1901
Aflibercept is already approved in United States, European Union for the following indications:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Metastatic Colorectal Cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
EyePoint Pharmaceuticals, Inc.
Lead Sponsor